This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Drs. Fox and Arnold1 provide a useful perspective on the recent head-to-head trials comparing interferon beta-1b and subcutaneous interferon beta-1a with glatiramer acetate.
The BECOME and REGARD trials2,3 reported almost identical clinical outcomes between high-dose interferons and glatiramer acetate. Both provide valuable information for physicians recommending therapy.
The authors of the editorial do not mention that, in the REGARD trial, brain atrophy was significantly less in patients randomized to glatiramer acetate vs subcutaneous interferon beta-1a. Atrophy continues to emerge as an MRI measure of some value in clinical trials of potential new multiple sclerosis …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease
Dr. Marianne de Visser and Dr. Maudy Theunissen
► Watch
Alert Me
Recommended articles
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
The challenge of follow-on biologics for treatment of multiple sclerosis